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Available online 31 October 2019 Background: The aim of our study was to evaluate the relevance of FGF23-klotho axis in the predisposition for 
bone fractures in type 2 diabetic patients with early chronic kidney disease. 
Methods: In a prospective study we included 126 type 2 diabetic patients with CKD stages 2–3 (from 2010 to 2017). 
We used descriptive statistics, ANOVA and chi-square test. Our population was divided into two groups according to 
the occurrence of a bone fracture event or not, and the groups were compared considering several biological and 
laboratorial parameters. We employed a multiple regression model to identify risk factors for bone fracture events 
and hazard ratios (HR) were calculated using a backward stepwise likelihood ratio (LR) Cox regression. 
Results: Patients with a fracture event displayed higher levels of FGF-23, Phosphorus, PTH, TNF-α, OxLDL, HOMA-IR, 
calcium × phosphorus product and ACR and lower levels of Osteocalcin, α-Klotho, 25(OH)D3 and eGFR compared 
with patients without a fracture event (p b 0.001). The number of patients with a fracture event was higher than 
expected within inclining CKD stages (χ2, p = 0.06). The occurrence of fracture and the levels of TNF- α, klotho,  
25(OH)D3 and OxLDL were found to predict patient entry into RRT (p b 0.05). Age, osteocalcin, α-Klotho and 
FGF-23 independently influenced the occurrence of bone fracture (p b 0.05). 
Conclusions: α-Klotho and FGF-23 levels may have a good clinical use as biomarkers to predict the occurrence of 
fracture events. 
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FGF-23 1. Introduction 
Chronic kidney disease (CKD) is a worldwide condition associated 
with high mortality and morbidity rates.1 It is well established that 
abnormalities in mineral metabolism are apparently early in the course 
of CKD and play a major role in accelerating metabolic abnormalities 
associated with CKD.1 One of the well-known consequences of CKD is 
predisposition to fragility fractures. Not only is the risk of fracture higher 
in the CKD population, but clinical outcomes are significantly worse.2 
This is a particularly critical health burden in patients with diabetes, 
who are at a higher risk for bone fracture than a non-diabetic person.3,4 
Contrary to what should be expected, and despite their elevated bone 
mineral density (BMD), patients with Type 2 diabetes mellitus (T2DM), 
are at an increased risk of fracture. In 2017, a systematic review and 
meta-analysis of published data on the association between diabetes mellitus and fracture, showed the association between T2DM and 
increased risk of overall fracture.5 
The primary function of bone is to maintain its structural integrity 
though a constant process of bone remodeling. Moreover, bone is also a 
key player in the regulation of mineral metabolism. More recently, bone 
was also recognized as an endocrine organ that releases two important 
hormones, fibroblast growth factor 23 (FGF-23) and undercarboxylated 
osteocalcin (Ocn).6,7 FGF-23 regulates phosphate and vitamin D metabo­
lism and Ocn is an essential in energy metabolism, and sexual 
reproduction.8 
Both FGF-23 and Ocn levels are increased in CKD, making these pro­
teins promising potential bio-markers for bone remodeling in CKD.9,10 
In addition, there are emerging data supporting that CKD patients 
with T2DM are at an increased risk for adynamic bone disease.11 
In order to better prevent the occurrence of skeletal fracture it is 
important to better understand which could be the best biomarkers 
predisposing for bone fractures in populations at risk. In the present 
study, our main goal was to clarify the role of some bone related bio­
chemical parameters and hormone levels in the predisposition for 
bone fractures in T2DM patients with CKD. 
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Table 1 
Patients demographic and clinical characteristics at baseline. Chronic kidney disease 
(CKD) patients with type 2 diabetics (T2DM), with and without the occurrence of bone 
fracture and a control population of healthy subjects. 
Variable Fracture (no) Fracture (yes) Control 
(n = 100) (n = 26) (n = 27) 
Age (years) 56.99 ± 6.69 61.15 ± 6.60 59.30 ± 5.69 
Osteocalcin (μg/L) 20.82 ± 0.67 8.88 ± 1.30 * 23.67 ± 1.10 
α-Klotho (pg/mL) 379.08 ± 15.07 113.31 ± 13.89 * 490.67 ± 8.76 * 
FGF-23 (RU/mL) 111.01 ± 13.41 304.63 ± 27.02 * 60.97 ± 1.70 
25(OH)D3 (ng/mL) 22.73 ± 0.71 14.27 ± 1.06 * 25.87 ± 0.39 
OxLDL (U/L) 36.81 ± 1.82 59.15 ± 4.44 * 29.65 ± 0.81 
TNF-α (pg/mL) 7.55 ± 0.32 11.32 ± 0.90 * 5.90 ± 0.15 
HOMA-IR 1.55 ± 0.16 3.04 ± 0.23 * 0.55 ± 0.01 ** 
Calcium × Phosphorus (mg/dL) 35.95 ± 0.91 43.56 ± 1.40 * 28.47 ± 1.38 * 
ACR (μg/mg) 161.22 ± 1.10 261.18 ± 25.01* 114.70 ± 10.36 
PTH (pg/mL) 100.35 ± 7.09 177.05 ± 16.34 * 73.30 ± 1.85 
Phosphorus (mg/dL) 3.82 ± 0.08 4.52 ± 0.15 * 3.23 ± 0.14 * 
Calcium (mg/dL) 9.52 ± 0.07 9.08 ± 0.50 8.97 ± 0.13* 
eGFR (mL/min) 51.95 ± 1.66 41.02 ± 1.82 * 103.53 ± 1.37 * 
Values are presented as mean ± standard deviation. *p b .001; **p b .005. All comparisons 
were made relative to CKD patients (and T2DM) without a fracture event. 2. Material and methods 
2.1. Subjects 
In an observational prospective study, we included 126 CKD patients 
with T2DM and 26 healthy individuals, recruited between 2010 and 
2017 with a diagnosis of diabetic nephropathy (stages 2–3) in a stable 
clinical condition attending our outpatient clinic. 
Institutional Ethics Committee approval (reference 207/2010) was 
obtained for this study. 
The exclusion criteria were: Previous bone disease, age b 18 years or 
N75 years, uncontrolled hypertension (BP ≥ 140/90 mmHg), albumin-
to-creatinine ratio (ACR) N500, estimated glomerular filtration rate 
(eGFR) ≤29 or N90 mL/min, type1 diabetes, known neoplastic or infec­
tious diseases, non-diabetic renal disease (patients without previous 
history of diabetes, with diagnosis of glomerulopathies associated 
with other pathologies like systemic diseases, IgA nephropathy, kidney 
disease of unknown ethology, chronic interstitial nephritis, vasculitis, 
component complement 3 pathologies or renal hereditary diseases. 
Patients with parathyroid hormone (PTH) ≥ 350 pg/mL were excluded 
to avoid bias from anti-hyperparathyroidism medication that can affect 
Klotho and FGF-23 levels. The same happened with patients with 
phosphorus N5.5 and the phosphorus-chelating agents that affect the 
Klotho-FGF-23 axis. Patients undergoing therapy with vitamin D and 
vitamin D receptor activators and phosphate binders, as well as antico­
agulant therapies (varfine, enoxaparin, clopidogrel, and platelet 
antiaggregant) were also excluded. 
2.2. Follow-up 
Patients returned on a regular basis (every 3 months) for in-person 
visits on Nephrology consultation. No patient was “lost to follow-up”. 
2.3. Blood measurements 
Fasting samples were drawn from all subjects, and plasma was 
frozen at −80 °C in order to measure glomerular filtration rate (eGFR), 
phosphorus (P), calcium (Ca), osteocalcin (Ocn), hemoglobin (Hg), 
glycated hemoglobin (HbA1c), PTH, colesterol, albumine to creatinine 
ratio (ACR), insulin resistance degree (HOMA-IR), fibroblast growth 
factor-23 (FGF-23), 25(OH)D3 (vitamin D), oxidized low density lipo­
protein (OxLDL), tumor necroses factor- alpha (TNF- α), and soluble 
α-Klotho (Klotho). FGF-23 levels were quantified using an enzyme-
linked immunosorbent assay, Human FGF-23 (C-Term) (Cat.#60-6100 
Immutopics Inc., San Clemente, CA, USA) and Human soluble α-
Klotho ELISA kit (Code No. 27998, IBL – Immuno-Biological Laboratories 
Co., Ltd., Gunma, Japan), according to the manufacturer's instructions. 
The degree of insulin resistance was estimated using the homeostasis 
model assessment (HOMA-IR) described by Matthews et al.12 We esti­
mated the GFR according to the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) Equation.13 
2.4. Outcomes 
The primary outcome of this study was occurrence of bone fracture. 
2.5. Statistical analyses 
Statistical analysis was performed with SPSS17.0 for Windows. 
Descriptive statistics, Chi-square and logistic regression were used. to 
compare CKD patients with or without the occurrence of bone fracture 
event to a control healthy population, we used ANOVA and a post-hoc 
analysis with Scheffe test. Continuous variables were presented as 
mean ± standard error. A value of b0.05 was considered significant. 
The hazard ratios (HR) were calculated using a backward stepwise 
likelihood ratio (LR) Cox regression for entry into renal replacement therapy (RRT). The logistic regression model was used to determine 
whether the variables were important predictive factors in the determi­
nation of occurrence of bone fracture event. Only the variables with a 
statistically significant relationship were introduced in a logistic regres­
sion model. The exponentials of the model parameters were the 
adjusted odds ratio (ORa) to other variables of the model. Prior to 
conducting the logistic regression and the Cox regression, subjects 
were categorized according to the 25th, 50th and 75th percentiles of 
FGF-23, Klotho, osteocalcin, phosphorus and oxLDL levels in the current 
study population were determined to exclude confounding factors that 
may influence the results. The subjects were categorized as follows: for 
FGF-23 group 1 (FGF-23 b 58), group 2 (FGF-23: 58–100) and group 3 
(FGF-23 N 100); for Klotho group 1 (Klotho b 268), group 2 (Klotho: 
268–440) and group 3 (Klotho N 440); for osteocalcin group 1 (Ocn 
b 16), group 2 (Ocn: 16–24) and group 3 (Ocn N 24); for phosphorus 
group 1 (phosphorus b 3.7), group 2 (phosphorus: 3.7–4.6) and group 
3 (phosphorus N 4.6) and for oxLDL group 1 (oxLDL b 27), group 2 
(oxLDL: 27–36) and group 3 (oxLDL N 36). CKD stages were defined 
by the eGFR (mL/min/1.73m2), for Stage 2 (eGFR 60–89), for Stage 3a 
(eGFR 45–59), for Stage 3b (eGFR 30–44). The null hypothesis was 
rejected below the level of 5%. 
3. Results 
One hundred and twenty-six (126) consenting patients with type 2 
diabetes mellitus (T2DM) and stage 2–3 of chronic kidney disease 
(CKD) were included in the study after confirming they did not meet 
any of the exclusion criteria. A negative control of 26 healthy individuals 
was also incorporated in the study. The mean age was 58.10 ± 6,66 
[range 41–68] years, and 41.8% (64) were female. 
Subjects were classified into three groups: CKD patients (and T2DM) 
with a fracture event, CKD patients (and T2DM) without a fracture 
event and a control population of healthy subjects. Table 1 displays 
patients' demographic and clinical parameters and a comparison 
between CKD patients (and T2DM) with a fracture event, CKD patients 
(and T2DM) without a fracture event and a control population of 
healthy subjects. 
In Table 1 and Fig. 1, mean values of osteomineral parameters for 
CKD patients with T2DM, with and without the occurrence of bone 
fracture and for a control population of healthy individuals are listed. 
CKD Patients with a fracture event displayed lower values for 
Osteocalcin (p b 0.001), α-Klotho (p b 0.001), and 25(OH)D3 (p b 0.001) 
when compared to both CKD patients without a fracture event and the 
control healthy subjects. Furthermore, CKD patients without a fracture 
event displayed lower α-Klotho (p b 0.01) when compared to control 
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Fig. 1. Parameters of mineral metabolism in Chronic kidney disease (CKD) patients with type 2 diabetics (T2DM) with and without a fracture event. Results of post hoc analysis: ** p b .001 
vs no fracture; ∝ p b .01 vs control. healthy subjects. On the other hand, the levels of FGF-23 (p b 0.001), Phos­
phorus (p b 0.001) and PTH (p b 0.001) are increased in CKD patients with 
a fracture event. Moreover, the phosphorus levels of CKD patients without 
a fracture event are higher than those of the control population. 
In Fig. 2, mean values of other parameter, such as inflammatory, 
oxidative stress, cardiovascular and kidney function markers are listed. 
TNF-α (p b 0.001), OxLDL (p b 0.001), HOMA-IR (p b 0.001), calcium 
× phosphorus product (p b 0.001) and ACR (p b 0.001) are increased 
in CKD patients with a fracture event. Both HOMA-IR (p b 0.001) and 
calcium × phosphorus product (p b 0.001) are also increased in the 
CKD patients without a fracture event when compared to the healthy 
control subjects. eGFR levels were lower in all CKD patients but even 
lower in CKD patients with a fracture event (p b 0.01). 
Fig. 3 shows the occurrence of a fracture event according to the stage 
of renal disease. The patients were classified into three stages of CKD, according to the eGFR (mL/min/1.73 m2): stage 2 (60–89), stage 3a 
(45–59) and stage 3b (30–44). The patients with a fracture event 
increase with inclining CKD stages (χ2, p = 006). 
To evaluate the ORa of osteomineral parameters for CKD patients 
with T2DM, that are predictors of bone fracture event, a model of logis­
tic regression analyses was used. All comparisons were made relative to 
the reference value of each osteomineral parameter. The logistic regres­
sion analysis (Table 2) revealed that age, osteocalcin, α-Klotho and FGF­
23 independently influenced the occurrence of bone fracture (p b 0.05). 
Variables such as gender, age, phosphorus, PTH, Osteocalcin, FGF-23, 
Klotho, 25(OH)D3, OxLDL and the occurrence of fracture were analyzed 
using a multivariate Cox regression to identify independent risk factors 
of entry into RRT. The occurrence of fracture and the levels of TNF- α, 
klotho, 25(OH)D3 and OxLDL were found to predict patient entry into 
RRT (p b 0.05) (Table 3). 
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Fig. 2. Parameters in Chronic kidney disease (CKD) patients with type 2 diabetics (T2DM) with and without a fracture event. Results of post hoc analysis: ** p b .001 vs no fracture; ∝ p b .01 
vs control. 4. Discussion and conclusion 
As worldwide life expectancy continues to rise, the burden of fragility 
fractures is a persistently growing health problem. Bone fractures result 
in considerable morbidity, reduced lifetime and bigger health care costs; 
thus, it is urgent to  find a good tool to identify patients with high fracture 
risk. The FRAX module identifies patients at risk of fracture considering 
the BMD, previous fracture, glucocorticoid use, and family history on 
the 10-year risk for fracture, as independent risk factors for fracture.14 
Identifying new biomarkers, such as hormones, for bone fragility would 
definitely improve this model as well as improve drug therapy to reduce 
fracture rates in high-risk populations. It is well established that diabetic 
CKD patients are at particularly high risk of bone fracture.15 Both low 
eGFR and higher albuminuria are considered significant risk factors for 
fracture.16 In this study, patients were classified into three stages of 
CKD, according to the eGFR (mL/min/1.73 m2): stage 2 (60–89), stage 
3a (45–59) and stage 3b (30–44). The number of patients with a fracture event was higher than expected within inclining CKD stages (χ2, p = 
0.06). Moreover, ACR are also increased in CKD patients with a fracture 
event (p b 0.001). 
In this study, we found that in a population of T2DM CKD patients 
(stage 2 and 3), age, osteocalcin, α-Klotho and FGF-23 levels indepen­
dently influenced the occurrence of bone fracture. Interestingly, the 
association of higher FGF23 and lower Klotho levels with fracture occur­
rence is independent of eGFR. 
Moreover, and using Cox analysis, the levels of TNF- α, klotho, 25 
(OH)D3 and OxLDL and the occurrence of fracture were found to inde­
pendently predict patient entry into RRT (p b 0.05). 
These findings reinforce the idea that hormones and osteomineral 
parameters related to bone remodeling may be good candidates as bio­
markers to predict the occurrence of fracture events. 
Maintaining physiological phosphate balance is of crucial biological 
importance for bone health. Others and ourselves, have previously 
demonstrated that hyperphosphatemia is associated with greater 
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Fig. 3. The occurrence of a fracture event according to Chronic kidney disease (CKD) stage. 
(Pearson Chi-Square, p = 006). The patients were classified into three stages of CKD, 
according to the eGFR (mL/min/1.73 m2): CKD 2 (60–89), CKD 3a (45–59) and CKD 3b 
(30–44). 
Table 2 
Predictive factors of fracture event. 
Variables ORa 95% CI p values 
Gender 
Male 
Female 
Ref. 
1.893 0.255–2.035 0.532 
Age 
b65 
≥65 
Ref. 
2.206 1.07–4.50 0.044 
CKD stages 
Stage 2 (60–89) 
Stage 3a (45–59) 
Stage 3b (30–44) 
Ref. 
6.183 
9.537 
0.993–1.900 
0.146–3.192 
0.395 
0.290 
Phosphorus 
≤3.6 
N3.6–4.6 
N4.6 
Ref. 
0.332 
1.058 
0.613–8.783 
0.846–4.586 
0.510 
0.972 
PTH 
b138 
≥138 
Ref. 
0.197 0.912–3.170 0.252 
HOMA-IR 
b2 
≥2 
Ref. 
1.783 0.221–8.169 0.193 
TNF-α 
b8 
≥8 
Ref. 
2.027 0.735–3.507 0.610 
Osteocalcin 
b16 
16–24 
N24 
1.016 
1.296 
Ref. 
1.001–1.389 
1.000–3.005 
0.045 
0.007 
α-Klotho 
b268 
268–440 
≥440 
1.226 
2.950 
Ref. 
1.001–1.678 
2.00–3.500 
0.058 
0.037 
FGF-23 
b58 
58–101 
N101 
Ref. 
1.788 
3.853 
1.001–2.366 
2.020–7.428 
0.024 
0.015 
25(OH)D3 
≥21 
b21 
Ref. 
0.203 0.702–2.427 0.201 
OxLDL 
b27 
27–36 
Ref. 
1.032 0.351–3.021 0.138 
Logistic regression model: ORa adjusted odds ratio, 95% CI confidence interval for the odds 
ratio, Ref category versus the one is making comparisons. cardiovascular mortality and morbidity even in patients in low to 
moderate stages of renal disease.17–19 In the present study we showed 
that the levels of Phosphorus are specially increased in CKD patients 
with a fracture event (p b 0.001). 
FGF-23 is a key player in the homeostasis of serum phosphate 
levels.20 This hormone is secreted by osteocytes and osteoblasts in 
response to high phosphate levels, either caused by dietary phosphate 
intake or due to states of impaired renal excretion, such as chronic 
kidney disease.21,22 FGF-23 stimulates urinary phosphate excretion by 
suppressing type IIa sodium phosphate co-transporter in the renal 
proximal tubule.20 In the gut, FGF-23 reduces the efficiency of phos­
phate absorption by impairing production and accelerating degradation 
of the active form of vitamin D.23 Recent data suggest that FGF-23 
can also directly inhibit the expression and secretion of PTH but, by pro­
moting 1,25(OH)2D3 deficiency it may also contribute to the develop­
ment of secondary hyperparathyroidism.24 Both PTH and vitamin D 
levels have been previously demonstrated to be informative for the 
definition of fracture risk in patients with CKD-mineral and bone 
disorders, being useful tools for the identification of CKD patients at 
high risk of fracture.25,26 In agreement with this, our results showed 
that, on the one hand, FGF23 and PTH levels were increased in CKD pa­
tients with a fracture event (p b 0.001), on the other hand, CKD patients 
with a fracture event displayed lower values for 25(OH)D3 (p b 0.001) 
when compared to both CKD patients without a fracture event and 
the control healthy subjects. Excessive levels of FGF-23 are associated 
with bone disorders such as tumor-induced osteomalacia. In these path­
ological conditions, FGF-23-dependent phosphaturia and calcitriol defi­
ciency leads to severe bone loss, as well as to bone pain and fractures.27 
Despite the numerous studies supporting that FGF-23 is a negative reg­
ulator of bone matrix mineralization both in vivo and in vitro28,29, the  
relationship between FGF-23 elevation (in early CKD) and fracture risk 
is still a matter of debate due to conflicting results.21,30–32 Some studies 
demonstrate an independent association between higher FGF-23 levels 
and greater fracture risk in elderly men31,32; whereas cross-sectional 
studies investigating the association of FGF-23 with bone mineral den­
sity have also showed contradictory results,30,33,34 with the majority 
reporting no significant associations.21,30,34 In the present study we 
observed a relationship between elevated FGF-23 levels and fracture 
risk in the studied population of T2DM patients with low to moderate 
CKD. This is in agreement with previous studies reporting that FGF-23 
was also found to be a predictor of CKD progression in diabetic35 and 
non-diabetic patients.36 Interestingly, numerous data on pleotropic 
effects of FGF-23 is also emerging, namely the association of elevated 
FGF-23 levels with multiple cardiovascular risk factors37–39 and 
mortality.40 All together, this makes FGF-23 a potential biomarker of 
multiple disarrangements leading to negative patient outcome. In the majority of cases, FGF-23 signal transduction requires a 
binding to FGF receptor and α–Klotho protein.41 Soluble Klotho is a 
multi-function protein present in the blood, urine, and cerebrospinal 
fluid and plays important roles in anti-aging, energy metabolism, 
inhibition of Wnt signaling, anti-oxidation, ion transport, control of 
PTH and 1,25(OH)2VD3 production, inhibition of insulin and antago­
nism of renin-angiotensin-aldosterone system. α–Klotho is stimu­
lated by 1,25(OH)2VD3 and inhibited by FGF-23 thereby creating an 
endocrine loop, as circulating Klotho can activate FGF-23-FGFR 
signaling.42 In the majority of clinical studies CKD has been described 
has a state of FGF-23 resistance due to endocrine and renal Klotho 
deficiency.43 
In this study, lower levels of Klotho seem to be an independent pre­
dictive factor for bone fracture, in T2DM patients with CKD. Interestingly, 
data suggesting that TNF-α is able to downregulate Klotho expression,44 
is also in line with our results, showing increased levels of the inflamma­
tory cytokine TNF-α and decreased levels of Klotho in type 2 diabetic pa­
tients with CKD with a fracture event. Thus, it is not unreasonable to 
hypothesize that elevated Klotho levels may serve as an early biomarker 
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Table 3 
Predictive factors for entry into renal function replacement technique. 
Variables Adjusted HR 95% CI p values 
Gender 
Female 
Male 
Ref. 
3.702 0.670–2.462 0.133 
Age 
b65 
≥65 
Ref. 
0.385 0.048–3.067 0.385 
ACR 
b95 
95–235 
N235 
Ref. 
2.133 
2.573 
0.126–36.041 
1.935–6.133 
0.600 
0.050 
Phosphorus 
≤3.6 
N3.6–4.6 
N4.6 
Ref. 
0.590 
0.333 
0.031–1.192 
0.012–9.507 
0.725 
0.520 
PTH 
b138 
≥138 
Ref. 
3.669 0.270–4.797 0.329 
Fracture 
No 
Yes 
Ref. 
8.036 1.267–9.988 0.027 
TNF-α 
b8 
≥8 
Ref. 
1.076 1.001–4.755 0.014 
Osteocalcin 
b16 
16–24 
N24 
1.442 
3.684 
Ref. 
3.023–1.080 
0.421–9.849 
0.889 
0.907 
α-Klotho 
b268 
268–440 
≥440 
6.762 
1.159 
Ref. 
0.872–8.718 
1.010–2.523 
0.060 
0.042 
FGF-23 
b58 
58–101 
N101 
Ref. 
3.910 
0.485 
0.725–6.839 
0.203–1.847 
0.081 
0.776 
25(OH)D3 
≥21 
b21 
Ref. 
2.184 1.824–3.125 0.009 
OxLDL 
b27 
27–36 
N36 
Ref. 
1.183 
2.543 
1.081–2.758 
1.406–2.368 
0.040 
0.026 
Multivariate Cox regression: HR hazard ratio. 95% CI confidence interval for the HR. Ref 
category versus the one is making comparisons. and a pathogenic contributor to chronic progression and complications 
in chronic kidney disease, such as bone fragility. 
However, it is still controversial whether osteocalcin is a good marker 
of bone formation4546 and the fact that initially OC was believed to 
be only necessary to maintain the normal calcification and inhibit 
mineralization, more recently a much wide role of OC has been sug­
gested in overall body metabolism, reproduction, cognition as well as 
regulating insulin production and secretion.47 Our results show that, 
not only do low levels of OC independently influenced the risk for bone 
fracture in T2DM CKD patients, but patients with a bone fracture event 
also presented higher HOMA-IR values when compared to the ones 
without a fracture event, at least considering the population in this 
study. This is in line with previous results from Xuefei et al., showing 
that OC might improve glucose metabolism through increasing insulin 
secretion and improving insulin resistance in females with T2DM.48 
Despite some limitations, namely the small size of the sample and 
the limited statistical power of these analyses, this study offers an added value by generating hypotheses. Nonetheless, further studies 
are required in order to confirm the observed associations. 
In conclusion, the present study strongly suggests that a deregula­
tion in mineral metabolism, reflected by low levels of Osteocalcin and 
Klotho and high levels of FGF-23, could be associated with an increased 
risk of bone fracture in T2DM patients with a diagnosis of mild to 
moderate CKD. 
We believe the assessment of fracture risk can be better predicted by 
using a combination of biochemical markers of bone turnover - which 
are dynamic markers, and the BMD measurement - which provides a 
static picture of the skeleton, than by assessing either alone. 
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